Red Flags Detected
- Material Weakness (worsened) — Material weaknesses expanded from two deficiencies (segregation of duties, insufficient policies) to four, adding lack of accounting systems and insufficient expense report controls, and now apply to all prior periods.
GLSI reports worsening internal controls, 36% cash burn rise as Phase III trial scales
Filed June 1, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read
Key Changes
-
high
Material weaknesses in internal controls expanded from two deficiencies to four, adding lack of accounting systems for financial reporting/stock awards and insufficient expense report controls. Management now identifies weaknesses across all prior periods, not just Q3 2020.
Controls & Risk Factors verify on EDGAR → -
high
Operating cash burn jumped 36% to $9.9M (from $7.3M prior year) as Phase III Flamingo-01 trial expanded, outpacing the 11% increase in reported R&D expense and suggesting accelerated trial-related payments.
MD&A: Cash Flow verify on EDGAR → -
high
Net loss rose 12% to $19.4M (vs. $17.4M restated prior year), driven by Phase III trial costs. Accumulated deficit deepened to $87.1M from $66.2M, reflecting sustained pre-revenue burn.
MD&A & Risk Factors verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.
Partner
Trade GLSI commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 10, 2026 7:25 PM